Sirolimus early graft nephrotoxicity: clinical and experimental data

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Sirolimus (SRL) is a macrolide immunosuppressant targeting mTOR signaling.
• SRL is used post-renal transplantation to prevent acute rejection.
• SRL's nephrotoxicity, especially with calcineurin inhibitors, requires further investigation.

Purpose of the Study:

• To review clinical and experimental data on Sirolimus-induced nephrotoxicity after renal transplantation.
• To discuss the mechanisms and long-term consequences of SRL nephrotoxicity.

Main Methods:

• Review of clinical data on Sirolimus use in renal transplant patients.
• Analysis of experimental studies investigating SRL's effects on renal tubular cells.
• Examination of long-term outcomes including proteinuria and graft survival.

Main Results:

• SRL alone shows minimal nephrotoxicity in normal conditions.
• Concomitant use with calcineurin inhibitors increases serum creatinine.
• Early SRL administration may delay graft function recovery by inhibiting tubular repair.
• Long-term SRL use is linked to increased proteinuria and potential graft loss.

Conclusions:

• Sirolimus-induced nephrotoxicity is a significant concern in renal transplantation.
• Understanding SRL's impact on renal function is crucial for patient management.
• Further research is needed to elucidate synergistic nephrotoxic mechanisms and mitigate risks.